Physician profile
Terance Chi
NPI 1225367402
$2,052.46
in general payments reported to CMS, 2019-2025
24 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what 96% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.14 · 2022: $183 · 2023: $58.86 · 2024: $479 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,824.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $391.55 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $325.25 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $178.75 | 2025 | Zoryve |
| Amgen INC. | $168.16 | 2024-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.24 | 2021-2022 | |
| Exact Sciences Corporation | $113.96 | 2024-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $105.10 | 2024-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.08 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $84.57 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $77.02 | 2024-2025 | |
| Esperion Therapeutics, INC. | $47.07 | 2025 | Nexletol |
| Sumitomo Pharma America, INC. | $43.30 | 2024-2025 | Gemtesa |
| Madrigal Pharmaceuticals | $41.54 | 2025 | Rezdiffra |
| Ardelyx, INC. | $34.81 | 2023 | Ibsrela |
| Uswm, LLC | $30.88 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $28.63 | 2024 | Gvoke Hypopen |
| Seqirus USA INC | $20.93 | 2025 | Fluad, Flucelvax |
| Sanofi-Aventis U.S. LLC | $20.79 | 2025 | |
| Pfizer INC. | $20.55 | 2022 | |
| Opko Pharmaceuticals, LLC | $18.55 | 2022 | |
| Corcept Therapeutics | $18.30 | 2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $18.18 | 2025 | Ajovy |
| Astellas Pharma US INC | $16.42 | 2024 | Veozah |
| Lilly USA, LLC | $13.83 | 2024 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terance Chi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.